TokenPost·
Cumberland Pharmaceuticals Posts $2.16 Million Q3 Revenue, $0.07 Loss Per Share From Continuing Operations
GAAP net income reached $77.8 million, including an $81.1 million gain on disposal of discontinued operations.
More news
- TokenPostAgilyx Posts EUR 3.6 Million Q3 EBITDA as Year-to-Date Figure Turns Positive
- TokenPostDundee Corporation Posts Diluted EPS of $0.53 for Q3 2026
- The DefiantEthlabs Puts Ethereum Quantum Defense Ahead of Speed
- TokenPostXRP Funding Reaches 10.4% Annualized as Open Interest Falls 6.73%
- TokenPostWorldFoundry Adds Shared Evaluation Tools for Generative World Models
- TokenPostRallybio Sets 1-for-2 Reverse Split Ahead of Avenzo Merger